Toronto General Hospital
Cyclosporine microemulsion and tacrolimus are comparable in graft recipients
Published in Pharma Law Weekly, August 24th, 2004
"This is the first multicenter, randomized, open-label study to compare the efficacy and safety of cyclosporine A microemulsion (CsA-ME) (Neoral, Novartis, Basel, Switzerland) with C2 monitoring versus tacrolimus in de novo liver transplant recipients. Patients were stratified according to hepatitis C virus status and randomized to receive CsA-ME (n = 250) or tacrolimus (n = 245) with steroids, with or without azathioprine. The primary endpoint was the incidence of biopsy-proven acute rejection (BPAR) at 3 months," scientists in Canada report.
"Secondary endpoints included...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
Source: Pharma Law Weekly (2004-08-24)
More Articles from Pharma Law Weekly
- Abgenix, Inc.
Biotech company reports quarterly loss of $0.76 per share - American Bio Medica Corporation
Biotech company granted patents related to fluid sample device - American HomePatient, Inc.
Home care firm calls for action to protect access to respiratory medication - Aon Consulting
Firm offers advice on new CMS guidance on retiree drug coverage - Apria Healthcare Group, Inc.
Apria comments on proposed reimbursement for inhalation drugs - Association of Community Cancer Centers
Reductions in Medicare payment for drugs could impact continuum of cancer care - More from this issue of Pharma Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
